EMediNexus, a healthcare advocacy platform, surveyed a total of 4,892 doctors to understand their sentiments as they are "directly affected" by the Health Ministry's ban.
The ministry on March 14 banned altogether 344 fixed dose combinations, including cough syrups compositions, saying they involve "risk" to humans and safer alternatives were available.
Around 80 per cent of the doctors were found to prescribe drugs from the list of 344 drugs before the ban, the survey said.
Codeine and Nimesulide combinations were the main exceptions to the ban that doctors felt should have been made, amongst a vast list of other combinations, it said.
"As a healthcare advocacy platform, it was important to conduct this survey to understand the sentiments of doctors who are directly affected by the ban. The results were that 60 per cent of the doctors supported the ban while 40 per cent found it an unnecessary move," Amit Sharma and Nilesh Aggarwal, co-Founders eMediNexus, said in a joint statement.
The 344 banned drugs include the fixed dose combination of Chlopheniramine Maleate and Codeine syrup sold under the popular cough syrup brand Corex.
Fixed dose combination drugs are combinations of two or more active drugs in a single dose form.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
